Mental Illnesses Treatment Support & Programs NAMI Advocacy Find Your Local NAMI NAMIWalks
 | Print this page | 

Untitled Document

FDA Investigates Two Deaths Following Injection of Long-Acting Antipsychotic Zyprexa Relprevv

The U.S. Food and Drug Administration (FDA) has announced that it is investigating two unexplained deaths in patients who received an intramuscular injection of a new compound, the antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). Zyprexa Relprevv is a long-acting antipsychotic used in the treatment of schizophrenia. NAMI is monitoring information as it becomes available. Patients and caregivers should talk to their doctors with any questions or concerns. See the FDA Notice for more information.

Copyright Date: 06/18/2013

Post a Comment, Share on Facebook

 | Print this page | 


Support NAMI to help millions of Americans who face mental illness every day.

Donate today

Speak Out

Inspire others with your message of hope. Show others they are not alone.

Share your story

Get Involved

Become an advocate. Register on to keep up with NAMI news and events.

Join NAMI Today
  • Follow NAMI
  • Contact Us
    • NAMI
    • 3803 N. Fairfax Dr., Suite 100
    • Arlington, Va 22203
    • Main: (703) 524-7600
    • Fax: (703) 524-9094
    • Member Services: (888) 999-6264
    • Helpline: (800) 950-6264